|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
10
|
|
pubmed:dateCreated |
2002-10-18
|
|
pubmed:abstractText |
Tumor necrosis factor-alpha (TNF-alpha) is an important cytokine involved in the pathogenesis of inflammatory bowel disease. The monoclonal antibody to TNF-alpha, infliximab, is effective in treating Crohn's disease. Preclinical studies suggest the importance of TNF-alpha in treating ulcerative colitis (UC). We report the effectiveness of infliximab for UC and examine factors predictive of response to medication.
|
|
pubmed:commentsCorrections |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Oct
|
|
pubmed:issn |
0002-9270
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
97
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
2577-84
|
|
pubmed:dateRevised |
2004-11-17
|
|
pubmed:meshHeading |
pubmed-meshheading:12385442-Adult,
pubmed-meshheading:12385442-Aged,
pubmed-meshheading:12385442-Antibodies, Monoclonal,
pubmed-meshheading:12385442-Colitis, Ulcerative,
pubmed-meshheading:12385442-Female,
pubmed-meshheading:12385442-Humans,
pubmed-meshheading:12385442-Male,
pubmed-meshheading:12385442-Middle Aged,
pubmed-meshheading:12385442-Remission Induction,
pubmed-meshheading:12385442-Treatment Outcome,
pubmed-meshheading:12385442-Tumor Necrosis Factor-alpha
|
|
pubmed:year |
2002
|
|
pubmed:articleTitle |
Efficacy of anti-tumor necrosis factor therapy in patients with ulcerative colitis.
|
|
pubmed:affiliation |
Department of Medicine, University of Pennsylvania School of Medicine, Philadelphia 19104-4283, USA.
|
|
pubmed:publicationType |
Journal Article
|
